. Author manuscript; available in PMC: 2021 Mar 19.

Published in final edited form as: J Am Geriatr Soc. 2018 Oct 11;67(1):74–80. doi: 10.1111/jgs.15603

Table 4.

Unadjusted and Adjusted Associations Between Standardized Daily Dose (SDD) of Central Nervous System (CNS) Medications and Serious Falls and Hip Fracture

SDD	Crude	Adjusted¹
	Odds Ratio (95% Confidence Interval) P-Value
1–2 vs 0	1.00 (0.71–1.41) .99	1.03 (0.72–1.48) .86
≥3 vs 0	1.46 (1.04–2.05) .03	1.49 (1.03–2.14) .03
≥3 vs 1–2	1.45 (1.09–1.93) .01	1.44 (1.07–1.93) .02

Conditional logistic regression adjusted for race; ethnicity; cognitive function; walking aid use; vision impairment; wandering; Parkinson’s disease; urinary incontinence; Charlson Comorbidity Index (excluding dementia); other medications that may increase risk of falls, fracture, or syncope (non–serotonin norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, or tricyclic antidepressants; peripheral alpha-blockers; skeletal muscle relaxants; oral glucocorticoids); number of medications at baseline (excluding antidepressants, antiepileptics, antipsychotics, benzodiazepine receptor agonists, opioid receptor agonists, peripheral alpha blockers, skeletal muscle relaxants, acetylcholinesterase inhibitors, topical agents for the skin, multivitamins, laxatives, antidiarrheals); and CNS medication indications (anxiety, depression, seizure disorder, moderate/severe, dementia medications)